Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc.CRVS · Entity 4839 | Director | June 09, 2020 | June 12, 2020 |
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director | June 03, 2026 | June 05, 2026 |
| Gritstone bio, Inc.GRTS · Entity 80946 | Director | June 16, 2023 | June 21, 2023 |
| Guardant Health, Inc.GH · Entity 3238 | Director | September 16, 2026 | September 17, 2026 |
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corvus Pharmaceuticals, Inc.
Report date June 09, 2020 · Filed June 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.27 · Expires 2030-06-09 | Direct | 15,000 |
Reported balance
After 2020-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-09 · Grant · Acquired 15,000 · Balance 15,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
Denali Therapeutics Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,202 |
Reported balance
After 2026-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 6,408 · Balance 38,202 F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2: Includes 6,408 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.66 · Expires 2036-06-03 | Direct | 19,226 |
Reported balance
After 2026-06-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-03 · Grant · Acquired 19,226 · Balance 19,226 F4: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 781,797 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 781,797 F3: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2: Includes 6,408 unvested RSUs.
F3: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee.
F4: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Gritstone bio, Inc.
Report date June 16, 2023 · Filed June 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.19 · Expires 2033-06-15 | Direct | 51,800 |
Reported balance
After 2023-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-16 · Grant · Acquired 51,800 · Balance 51,800 F1: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date.
Guardant Health, Inc.
Report date September 16, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,906 |
Ending reported balance
After 2026-09-16 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-16 · Sale · Disposed 1,103 · Balance 13,477 F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $173.98 to $174.975. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Row 2 · 2026-09-16 · Sale · Disposed 3,300 · Balance 10,177 F2: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $175.02 to $176.01. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Row 3 · 2026-09-16 · Sale · Disposed 1,300 · Balance 8,877 F3: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $176.055 to $176.88. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Row 4 · 2026-09-16 · Sale · Disposed 971 · Balance 7,906 F4: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $177.08 to $177.945. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $173.98 to $174.975. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F2: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $175.02 to $176.01. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $176.055 to $176.88. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $177.08 to $177.945. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
PLIANT THERAPEUTICS, INC.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.14 · Expires 2036-06-11 | Direct | 70,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 70,000 · Balance 70,000 F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2021 Filed Jan 6, 2021 23:55 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $70.86 | $0.00 |
DisclosureSEC source: 0001209191-21-002352 · doc4.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-01-03 F3 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 4, 2022, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:55 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002352 · doc4.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units shall vest on January 4, 2022 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units shall vest on January 4, 2022 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 00:37 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Tax withholdingCommon Stock | 1,954 | $32.87 | $64,227.98 |
DisclosureSEC source: 0001209191-20-048173 · doc4.xml · nonDerivative · entry 2 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,006,511 F3 · kind: Shares withheld to satisfy the tax obligations by the reporting person in connection with the vesting of restricted stock units. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $32.835 to $32.89 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. Read SEC document |
| August 20, 2020 Filed Aug 25, 2020 00:37 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionRestricted Stock Units · Derivative | 5,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048173 · doc4.xml · derivative · entry 4 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,643 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F5 · derivative.exercise_date: 50% of the shares vested on August 20, 2019 and the remaining 50% of the shares vested on August 20, 2020. F5 · derivative.expiration_date: 50% of the shares vested on August 20, 2019 and the remaining 50% of the shares vested on August 20, 2020. Read SEC document |
| August 20, 2020 Filed Aug 25, 2020 00:37 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 5,643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-048173 · doc4.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,008,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F2 · ownership.nature: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:17 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-047793 · doc4.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units shall vest on August 18, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units shall vest on August 18, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 21:36 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001567619-20-012487 · doc1.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2030-06-18 F1 · derivative.exercise_date: The option will vest and become exercisable on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date. Read SEC document |
| June 09, 2020 Filed Jun 12, 2020 21:13 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001567619-20-012100 · doc1.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-09 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 22:19 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,428 | $19.48 | $27,817.44 |
DisclosureSEC source: 0001209191-20-022241 · doc4.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,006,488 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.46 to $19.49 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 21:29 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001567619-20-006908 · doc1.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-03-19 F1 · derivative.exercise_date: 100% of the shares subject to the option vest and become exercisable on the one-year anniversary of the grant date, subject to continued service as a director through such date. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:03 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 136,000 | $0.00 Strike: $24.81 | $0.00 |
DisclosureSEC source: 0001209191-20-008924 · doc4.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,000 Underlying: Common Stock · 136,000 shares Expires 2030-02-09 F3 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 10, 2021, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:03 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 29,143 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008924 · doc4.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,143 Underlying: Common Stock · 29,143 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units shall vest on February 10, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units shall vest on February 10, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 07, 2020 Filed Apr 1, 2020 22:16 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionRestricted Stock Units · Derivative | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-022237 · doc4a.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,750 Underlying: Common Stock · 4,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units vested on February 7, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units vested on February 7, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 07, 2020 Filed Apr 1, 2020 22:16 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 4,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-022237 · doc4a.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,007,916 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
| August 21, 2019 Filed Aug 22, 2019 23:48 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Tax withholdingCommon Stock | 1,977 | $18.59 | $36,745.31 |
DisclosureSEC source: 0001209191-19-047184 · doc4.xml · nonDerivative · entry 2 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,003,666 F2 · kind: Shares withheld to satisfy the tax obligations by the reporting person in connection with the vesting of restricted stock units. Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 23:48 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionRestricted Stock Units · Derivative | 5,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-047184 · doc4.xml · derivative · entry 3 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,643 Underlying: Common Stock · 5,643 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F3 · derivative.exercise_date: 50% of the shares subject to the option vested on August 20, 2019 and the remaining 50% shall vest on August 20, 2020, subject to the Reporting Person remaining a service provider of the Issuer through such date. F3 · derivative.expiration_date: 50% of the shares subject to the option vested on August 20, 2019 and the remaining 50% shall vest on August 20, 2020, subject to the Reporting Person remaining a service provider of the Issuer through such date. Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 23:48 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 5,643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-047184 · doc4.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,005,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 20:07 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0000899243-19-017924 · doc4.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common stock · 15,000 shares Expires 2029-06-20 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 20:12 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | GrantStock Option (Right to Buy) · Derivative | 8,570 | $0.00 Strike: $10.86 | $0.00 |
DisclosureSEC source: 0001567619-19-013756 · doc1.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,570 Underlying: Common Stock · 8,570 shares Expires 2029-06-19 F1 · derivative.exercise_date: The option will vest and become exercisable on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 22:56 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 136,000 | $0.00 Strike: $17.99 | $0.00 |
DisclosureSEC source: 0001209191-19-009068 · doc4.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,000 Underlying: Common Stock · 136,000 shares Expires 2029-02-06 F3 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 7, 2020, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 22:56 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-009068 · doc4.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units shall vest on February 7, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units shall vest on February 7, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 21:42 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 11,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-048025 · doc4.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,286 Underlying: Common Stock · 11,286 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 50% of the restricted stock units shall vest on August 20, 2019 and the remaining 50% shall vest on August 20, 2020, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 50% of the restricted stock units shall vest on August 20, 2019 and the remaining 50% shall vest on August 20, 2020, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 20:05 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.50 | $0.00 |
DisclosureSEC source: 0000899243-18-017912 · doc4.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-21 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| February 26, 2018 Filed Mar 1, 2018 00:56 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $22.16 | $0.00 |
DisclosureSEC source: 0001209191-18-014730 · doc4.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2028-02-25 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on February 26, 2019 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 12, 2017 Filed Dec 12, 2017 22:38 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-1 Preferred Stock · Derivative | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-065244 · doc4.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: The shares are held of record by The Steve Edward Krognes Revocable Trust, for which the Reporting Person serves as a trustee. Read SEC document |
| December 12, 2017 Filed Dec 12, 2017 22:38 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionCommon Stock | 500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-065244 · doc4.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,000,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: The shares are held of record by The Steve Edward Krognes Revocable Trust, for which the Reporting Person serves as a trustee. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 20:05 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.70 | $0.00 |
DisclosureSEC source: 0000899243-17-015931 · doc4.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-08 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2018 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.